Lung Cancer

TIGIT, a co-inhibitory receptor found on T cells and NK cells, transmits inhibitory signals upon binding to its ligand. This interaction suppresses the activation of various signaling pathways, leading to functional exhaustion of cells, ultimately …

Antibody-drug conjugates (ADCs) are an emerging class of therapeutics for lung cancer, and several are currently in development for this malignancy. The structure of these molecules is based on an antibody that targets a protein on the lung cancer …

Inequitable access to care continues to hinder improvements in diagnosis and treatment of lung cancer. This review describes healthcare disparities in the changing landscape of non–small cell lung cancer (NSCLC) in the United States, focusing on …

Arachnoid granulations (AGs) are protrusion of arachnoid membrane into dural sinuses. They function the transport of cerebrospinal fluid (CSF) from subarachnoid space into the venous system. AGs frequently protrude into the dural venous sinuses …

Lung cancer is an increasingly serious global public health concern due to its substantial incidence and its role as a leading cause of cancer-related death [ 1 ]. In 2020, there were 2,206,771 new cases of lung cancer and 1,796,144 related deaths …

Tumor-associated macrophages (TAMs) are abundant in tumors and interact with tumor cells, leading to the formation of an immunosuppressive microenvironment and tumor progression. Although many studies have explored the mechanisms underlying TAM …

The increase in the detection rate of synchronous multiple primary lung cancer (MPLC) has posed remarkable clinical challenges due to the limited understanding of its pathogenesis and molecular features. Here, comprehensive comparisons of genomic …

Lung neuroendocrine neoplasms (LNENs) account for one fifth of all pulmonary malignancies and comprise four histological subtypes with different clinical and biological characteristics [ 1 – 5 ]. Pulmonary carcinoids represent 10% of LNENs and …